Skip Ribbon Commands
Skip to main content
Sign In
Navigate Up

24970 Beta-Crosslaps (Beta-CTx), Serum (CTX)

Beta-Crosslaps (Beta-CTx), Serum (CTX)
Test Code: BCTXSO
Synonyms/Keywords
​Lab Ref Code:  83175, B-CTx, Beta CrossLaps, Beta-CTx, C-Telopeptide, C-terminal collagen crosslinks, Carboxy terminal collagen crosslinks, CTx
Useful For
An aid in monitoring antiresorptive therapies (eg, bisphosphonates and hormone replacement therapy) in postmenopausal women treated for osteoporosis and individuals diagnosed with osteopenia
 
An adjunct in the diagnosis of medical conditions associated with increased bone turnover
Specimen Requirements
Fasting Required Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)		 Pediatric Minimum Volume
(no repeat)
Fasting. Draw specimen prior to 10 a.m.​ Serum​ ​Red Top tube (RTT) ​Serum Separator Tube (SST) 1 mL​ ​0.4 mL ​
Specimen Stability Information
Specimen Type Temperature Time
​Serum Frozen (preferred) ​90 days
​ Refrigerated ​ ​72 hours
Rejection Criteria
Hemolysis
Mild OK; Gross reject
​Lipemia
Mild OK; Gross OK
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
Mayo Medical Laboratories​​
Monday through Friday; 5 a.m.-12 a.m., Saturday; 6 a.m.-6 p.m.
​
Same day/1 day
​
Electrochemiluminescence Immunoassay
​
Reference Lab
Mayo Clinic Laboratories
Reference Range Information
Reference Range
Males
<18 years: not established
18-30 years: 120-946 pg/mL
31-50 years: 93-630 pg/mL
51-70 years: 35-836 pg/mL
>70 years: not established
 
Females
<18 years: not established
Premenopausal: 25-573 pg/mL
Postmenopausal: 104-1,008 pg/mL
​
Interpretation
Elevated levels of beta-CTx indicate increased bone resorption. Increased levels are associated with osteoporosis, osteopenia, Paget's disease, hyperthyroidism, and hyperparathyroidism.
 
In patients taking antiresorptive agents (bisphosphonates or hormone replacement therapy), a decrease of > or =25% from baseline beta-CTx levels (ie, prior to the start of therapy) 3 to 6 months after initiation of therapy indicates an adequate therapeutic response.
​
Outreach CPTs
CPT Modifier
(if needed)		 Quantity Description Comments
​82523 ​ ​ ​ ​
Synonyms/Keywords
​Lab Ref Code:  83175, B-CTx, Beta CrossLaps, Beta-CTx, C-Telopeptide, C-terminal collagen crosslinks, Carboxy terminal collagen crosslinks, CTx
Ordering Applications
Ordering Application Description
​Centricity ​Beta-CrossLaps (B-Ctx), Serum (83175)
​Cerner ​None
​COM ​Beta-CrossLaps (B-CTx), Serum
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Fasting Required Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)		 Pediatric Minimum Volume
(no repeat)
Fasting. Draw specimen prior to 10 a.m.​ Serum​ ​Red Top tube (RTT) ​Serum Separator Tube (SST) 1 mL​ ​0.4 mL ​
Specimen Stability Information
Specimen Type Temperature Time
​Serum Frozen (preferred) ​90 days
​ Refrigerated ​ ​72 hours
Rejection Criteria
Hemolysis
Mild OK; Gross reject
​Lipemia
Mild OK; Gross OK
Useful For
An aid in monitoring antiresorptive therapies (eg, bisphosphonates and hormone replacement therapy) in postmenopausal women treated for osteoporosis and individuals diagnosed with osteopenia
 
An adjunct in the diagnosis of medical conditions associated with increased bone turnover
Reference Range Information
Reference Range
Males
<18 years: not established
18-30 years: 120-946 pg/mL
31-50 years: 93-630 pg/mL
51-70 years: 35-836 pg/mL
>70 years: not established
 
Females
<18 years: not established
Premenopausal: 25-573 pg/mL
Postmenopausal: 104-1,008 pg/mL
​
Interpretation
Elevated levels of beta-CTx indicate increased bone resorption. Increased levels are associated with osteoporosis, osteopenia, Paget's disease, hyperthyroidism, and hyperparathyroidism.
 
In patients taking antiresorptive agents (bisphosphonates or hormone replacement therapy), a decrease of > or =25% from baseline beta-CTx levels (ie, prior to the start of therapy) 3 to 6 months after initiation of therapy indicates an adequate therapeutic response.
​
For more information visit:
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
Mayo Medical Laboratories​​
Monday through Friday; 5 a.m.-12 a.m., Saturday; 6 a.m.-6 p.m.
​
Same day/1 day
​
Electrochemiluminescence Immunoassay
​
Reference Lab
Mayo Clinic Laboratories
For billing questions, see Contacts
Outreach CPTs
CPT Modifier
(if needed)		 Quantity Description Comments
​82523 ​ ​ ​ ​
For most current information refer to the Marshfield Laboratory online reference manual.